Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions reflect a positive reception to the article, with posts describing TC-325 as a potential game-changer in managing gastrointestinal bleeding, while others mention its cost-effectiveness and implications for standard care. The tone is generally analytical and slightly optimistic, emphasizing the significance of the findings for advancing treatment options.
Most discussions support the study’s findings that TC-325 is a promising first-line treatment and highlight its potential benefits.
Participants show moderate interest, with some posts emphasizing the importance of the research and its implications for treatment standards.
Posts reference specific aspects of the study, such as cost-utility and clinical benefits, indicating a thoughtful engagement.
The discussions suggest that the publication could influence clinical practice and future research directions regarding gastrointestinal bleeding treatment.
Cost-utility analysis: Hemostatic powder TC-325 as 1st-line treatment option for malignant GI bleeding Find the article at: https://t.co/HPfSFptySs Dawn M. Cooper et al. https://t.co/1deFWirJbX
Hemostatic powder TC-325 as first-line treatment option for malignant #gastrointestinal #bleeding #some4surgery https://t.co/gDR7635lZy
#AuthorCommentary: Dawn Cooper on "Hemostatic powder TC-325 as first-line treatment option for malignant gastrointestinal bleeding: a cost–utility analysis in the United Kingdom" Watch here: https://t.co/LecLNfGCF6 Read: https://t.co/HPfSFptySs Dawn M. Cooper et al.
A new study published in Endoscopy demonstrates that Hemospray could be a first-line treatment for MUGIB. Could Hemospray become the standard in malignant #GIbleed management? Dive into the full analysis-> https://t.co/YSnxmDkoVt #Endoscopy Product IFU: https://t.co/akxOei9Frs https://t.co/CTsRocVE9K
RT @endoscopyjrnl: Cost-utility analysis: Hemostatic powder TC-325 as 1st-line treatment option for malignant GI bleeding Find the article…
RT @CookMedSurg: A new study published in Endoscopy demonstrates that Hemospray could be a first-line treatment for MUGIB. Could Hemospray…
Dawn Cooper discusses the cost-effectiveness of Hemostatic powder TC-325 as a first-line treatment for malignant gastrointestinal bleeding, highlighting its ability to reduce costs (£24,588 less) and improve patient…
#AuthorCommentary: Dawn Cooper on "Hemostatic powder TC-325 as first-line treatment option for malignant gastrointestinal bleeding: a cost–utility analysis in the United Kingdom" Watch here: https://t.co/LecLNfGCF6 Read: https://t.co/HPfSFptySs Dawn M. Cooper et al.
RT @endoscopyjrnl: Cost-utility analysis: Hemostatic powder TC-325 as 1st-line treatment option for malignant GI bleeding Find the article…
RT @endoscopyjrnl: Cost-utility analysis: Hemostatic powder TC-325 as 1st-line treatment option for malignant GI bleeding Find the article…
Cost-utility analysis: Hemostatic powder TC-325 as 1st-line treatment option for malignant GI bleeding Find the article at: https://t.co/HPfSFptySs Dawn M. Cooper et al. https://t.co/1deFWirJbX
RT @CookMedSurg: A new study published in Endoscopy demonstrates that Hemospray could be a first-line treatment for MUGIB. Could Hemospray…
A new study published in Endoscopy demonstrates that Hemospray could be a first-line treatment for MUGIB. Could Hemospray become the standard in malignant #GIbleed management? Dive into the full analysis-> https://t.co/YSnxmDkoVt #Endoscopy Product IFU: https://t.co/akxOei9Frs https://t.co/CTsRocVE9K
Hemostatic powder TC-325 as first-line treatment option for malignant #gastrointestinal #bleeding #some4surgery https://t.co/gDR7635lZy
EJ
SM
CD
AB
RN
TT